Alcohol Use Disorder With Cirrhosis and Renal Impairment
Mr. T is a 60-year-old man with severe alcohol use disorder (8-10 standard drinks daily for 20 years), Child-Pugh class B cirrhosis (bilirubin 2.2 mg/dL, albumin 2.7 g/dL, INR 1.6, controlled ascites), and CKD stage 3b (eGFR 36 mL/min/1.73 m2). He has hypertension and no history of seizures. He wants to stop drinking and has failed two outpatient attempts. He lives alone and has no reliable transport. He is medically stable but has mild thrombocytopenia. The team is considering naltrexone, acamprosate, disulfiram, or gabapentin, and whether to admit for withdrawal management. He has not had withdrawal seizures but had tremors and sweats on prior quit attempts.
1. Which anticraving medication would you consider for this patient, and how do hepatic and renal function change the choice?
Read the worked answer
Disulfiram is contraindicated: Child-Pugh B cirrhosis, thrombocytopenia, and likely poor supervision make hepatitis and psychotic reactions unacceptable. Naltrexone is hepatically metabolized and can be used in mild-to-moderate liver disease with baseline and periodic transaminases, but in decompensated cirrhosis the label cautions against it and the evidence is thin; it is contraindicated in acute hepatitis or liver failure. If chosen, monitor LFTs and stop for signs of hepatotoxicity, but this patient's synthetic dysfunction makes it less attractive.
Acamprosate is renally excreted and not hepatically metabolized; it is the safer liver choice, but eGFR 36 requires dose reduction (333 mg three times daily, not 666 mg three times daily) and it is contraindicated below 30. Adherence is a concern, and he has no transport. Gabapentin is renally dosed, may reduce drinking and withdrawal symptoms, and is not hepatotoxic, but it can cause sedation and falls and has misuse potential. I would discuss acamprosate with adjusted dosing or gabapentin, and consider naltrexone only with close monitoring and shared decision-making. Psychosocial treatment is essential regardless.
2. Should he be admitted for withdrawal management? Explain the risk assessment.
Read the worked answer
Heavy daily drinking for 20 years, prior tremors and sweats, cirrhosis, thrombocytopenia, CKD, living alone, and failed outpatient attempts raise the risk of complicated withdrawal. CIWA-Ar is a monitoring tool, not a risk-stratification tool; use a validated predictor such as PAWSS plus clinical judgment. He warrants inpatient medically supervised withdrawal.
Benzodiazepines are first-line, but in cirrhosis use short-acting agents with less hepatic oxidation (lorazepam or oxazepam), at the lowest effective dose, and monitor for encephalopathy and over-sedation. Give thiamine before glucose, folate, and multivitamins; monitor electrolytes, magnesium, and renal function; treat agitation without adding sedatives unnecessarily. Avoid relying on phenobarbital in decompensated liver disease. If he refuses admission, arrange a structured intensive outpatient program with daily medical review only if safe; otherwise document the risks. After stabilization, start anticraving medication and link him to addiction treatment.
3. What psychosocial and systems supports would make a relapse-prevention plan feasible?
Read the worked answer
Use integrated care: addiction psychiatry, hepatology, primary care, and pharmacy. Choose a medication with a dosing schedule he can manage; if acamprosate three times daily is impossible, gabapentin or naltrexone with monitoring may be more practical. Arrange transportation or telehealth, and involve a case manager. Offer CBT, motivational enhancement therapy, and mutual-help groups (AA, SMART Recovery, or online meetings). Address housing and social isolation.
Monitor abstinence with self-report and biomarkers such as phosphatidylethanol or urine ethyl glucuronide rather than relying on liver enzymes, which are confounded by cirrhosis. Discuss liver transplant evaluation if he meets criteria; many programs require six months of abstinence, but this should not be used to deny addiction treatment. Provide naloxone if opioids are ever prescribed. Document a clear follow-up plan and emergency contacts.